Century Therapeutics, Inc. Other Income and Expense
Century Therapeutics, Inc. (IPSC) reported Other Income and Expense of $1.98 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Other Income
us-gaap:NonoperatingIncomeExpense · last filed 2026-08-12
- Century Therapeutics, Inc. nonoperating income (expense) for the quarter ending 2026-06-30 was $1.98M, a 6.88% decline year-over-year.
- Century Therapeutics, Inc. nonoperating income (expense) for the quarter ending 2026-03-31 was $2.04M, a 14.47% decline year-over-year.
- Century Therapeutics, Inc. nonoperating income (expense) for the quarter ending 2025-12-31 was $1.41M, a 52.73% decline year-over-year.
- Century Therapeutics, Inc. nonoperating income (expense) for the quarter ending 2025-09-30 was $1.70M, a 52.12% decline year-over-year.
- Century Therapeutics, Inc. nonoperating income (expense) for fiscal 2025 was $7.62M, a 42.96% decline from fiscal 2024.
- Century Therapeutics, Inc. nonoperating income (expense) for fiscal 2024 was $13.36M, a 13.67% increase from fiscal 2023.
- Century Therapeutics, Inc. nonoperating income (expense) for fiscal 2023 was $11.75M, a 293.11% increase from fiscal 2022.
- Century Therapeutics, Inc. nonoperating income (expense) for fiscal 2022 was $2.99M.
| Period end | Nonoperating Income (Expense) 3 month | Nonoperating Income (Expense) 6 month | Nonoperating Income (Expense) 9 month | Nonoperating Income (Expense) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.98M 10-Q · filed 2026-08-12 | $4.02M 10-Q · filed 2026-08-12 | $5.43M derived: sum of 3 quarters · filed 2026-08-12 | $7.13M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $2.04M 10-Q · filed 2026-05-13 | $3.45M derived: sum of 2 quarters · filed 2026-05-13 | $5.15M derived: sum of 3 quarters · filed 2026-05-13 | $7.28M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $1.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $3.11M derived: sum of 2 quarters · filed 2026-03-12 | $5.24M derived: sum of 3 quarters · filed 2026-08-12 | $7.62M 10-K · filed 2026-03-12 |
| 2025-09-30 | $1.70M 10-Q · filed 2025-11-13 | $3.83M derived: sum of 2 quarters · filed 2026-08-12 | $6.21M 10-Q · filed 2025-11-13 | $9.20M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $2.12M 10-Q · filed 2026-08-12 | $4.51M 10-Q · filed 2026-08-12 | $7.49M derived: sum of 3 quarters · filed 2026-08-12 | $11.05M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $2.38M 10-Q · filed 2026-05-13 | $5.37M derived: sum of 2 quarters · filed 2026-05-13 | $8.93M derived: sum of 3 quarters · filed 2026-05-13 | $12.50M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $2.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $6.54M derived: sum of 2 quarters · filed 2026-03-12 | $10.11M derived: sum of 3 quarters · filed 2026-03-12 | $13.36M 10-K · filed 2026-03-12 |
| 2024-09-30 | $3.56M 10-Q · filed 2025-11-13 | $7.13M derived: sum of 2 quarters · filed 2025-11-13 | $10.37M 10-Q · filed 2025-11-13 | $13.87M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $3.57M 10-Q · filed 2025-08-14 | $6.82M 10-Q · filed 2025-08-14 | $10.31M derived: sum of 3 quarters · filed 2025-08-14 | $13.81M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $3.25M 10-Q · filed 2025-05-15 | $6.74M derived: sum of 2 quarters · filed 2025-05-15 | $10.24M derived: sum of 3 quarters · filed 2025-05-15 | $12.98M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $3.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $6.99M derived: sum of 2 quarters · filed 2025-03-19 | $9.73M derived: sum of 3 quarters · filed 2025-03-19 | $11.75M 10-K · filed 2025-03-19 |
| 2023-09-30 | $3.50M 10-Q · filed 2024-11-05 | $6.23M derived: sum of 2 quarters · filed 2024-11-05 | $8.26M 10-Q · filed 2024-11-05 | $9.91M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | $2.74M 10-Q · filed 2024-08-08 | $4.76M 10-Q · filed 2024-08-08 | $6.42M derived: sum of 3 quarters · filed 2024-08-08 | $7.43M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $2.02M 10-Q · filed 2024-05-09 | $3.68M derived: sum of 2 quarters · filed 2024-05-09 | $4.70M derived: sum of 3 quarters · filed 2024-05-09 | $5.08M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $1.66M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $2.67M derived: sum of 2 quarters · filed 2024-03-14 | $3.05M derived: sum of 3 quarters · filed 2024-03-14 | $2.99M 10-K · filed 2024-03-14 |
| 2022-09-30 | $1.01M 10-Q · filed 2023-11-09 | $1.40M derived: sum of 2 quarters · filed 2023-11-09 | $1.33M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $381.00K 10-Q · filed 2023-08-09 | $320.00K 10-Q · filed 2023-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |